Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo

Blood

Volumn 115, Issue 22, 2010, Pages 4412-4420

  Matheoud, Diana ^a   Perié, Leila ^a   Hoeffel, Guillaume ^a,b   Vimeux, Lene ^a   Parent, Isabelle ^a   Marañón, Concepción ^a,c   Bourdoncle, Pierre ^a   Renia, Laurent ^a,b   Prevost Blondel, Armelle ^a   Lucas, Bruno ^a   Feuillet, Vincent ^a   Hosmalin, Anne ^a  

^a INSTITUT COCHIN   (France)

^b AGENCY FOR SCIENCE   (Singapore)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MELANOMA CELL; MEMBRANE VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTIGEN PRESENTATION; APOPTOSIS; C57BL MOUSE; CELL SURVIVAL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGEN PRESENTATION; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; CROSS-PRIMING; DENDRITIC CELLS; IMMUNITY, CELLULAR; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; OVALBUMIN;

EID: 77953938474     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-255935     Document Type: Article

References (50)

1. Bevan MJ. Cross-priming. Nat Immunol. 2006; 7(4):363-365.
2. Rock KL. The ins and outs of cross-presentation. Nat Immunol. 2003;4(10):941-943.
3. Lizee G, Basha G, Tiong J, et al. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol. 2003;4(11):1065-1073.
4. Chen W, Masterman KA, Basta S, et al. Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol. 2004;34(1):194-199.
5. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-667.
6. Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity. 2002;17(2):211-220.
7. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392(6671): 86-89.
8. Huang FP, Platt N, Wykes M, et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med. 2000;191(3): 435-444.
9. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med. 2002;196(8):1079-1090.
10. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191(3):423-434.
11. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008; 8(4):279-289.
12. Hugues S, Mougneau E, Ferlin W, et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity. 2002;16(2):169-181.
13. Luckashenak N, Schroeder S, Endt K, et al. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity. 2008;28(4):521-532.
14. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol. 2003;171(11):5940-5947.
15. Albert ML. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol. 2004;4(3):223-231.
16. Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature. 2009;458(7234):78-82.
17. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9(5):353-363.
18. Skoberne M, Beignon AS, Larsson M, Bhardwaj N. Apoptotic cells at the crossroads of tolerance and immunity. Curr Top Microbiol Immunol. 2005; 289:259-292.
19. Maranon C, Desoutter JF, Hoeffel G, Cohen W, Hanau D, Hosmalin A. Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2004;101(16):6092-6097. (Pubitemid 38520533)
20. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol. 2001;166(6):3717-3723.
21. Harshyne LA, Zimmer MI, Watkins SC, Barratt-Boyes SM. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J Immunol. 2003;170(5):2302-2309.
22. Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A. 2004;101(9):3035-3040.
23. Lindquist RL, Shakhar G, Dudziak D, et al. Visualizing dendritic cell networks in vivo. Nat Immunol. 2004;5(12):1243-1250.
24. Asperti-Boursin F, Real E, Bismuth G, Trautmann A, Donnadieu E. CCR7 ligands control basal T cell motility within lymph node slices in a phosphoinositide 3-kinase-independent manner. J Exp Med. 2007;204(5):1167-1179.
25. Rotman B, Papermaster BW. Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. Proc Natl Acad Sci U S A. 1966;55(1):134-141.
26. Neijssen J, Herberts C, Drijfhout JW, Reits E, Janssen L, Neefjes J. Cross-presentation by intercellular peptide transfer through gap junctions. Nature. 2005;434(7029):83-88.
27. Pang B, Neijssen J, Qiao X, et al. Direct antigen presentation and gap junction mediated cross-presentation during apoptosis. J Immunol. 2009; 183(2):1083-1090.
28. Feuillet V, Semichon M, Restouin A, et al. The distinct capacity of Fyn and Lck to phosphorylate Sam68 in T cells is essentially governed by SH3/ SH2-catalytic domain linker interactions. Oncogene. 2002;21(47):7205-7213.
29. Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide- MHC class II complexes acquired from cell-based cancer vaccines. J Immunol. 2006;176(3): 1447-1455.
30. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76(1):17-27.
31. Nikolic-Zugic J, Carbone FR. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant. Eur J Immunol. 1990;20(11):2431-2437.
32. Mehal WZ, Azzaroli F, Crispe IN. Antigen presentation by liver cells controls intrahepatic T cell trapping, whereas bone marrow-derived cells preferentially promote intrahepatic T cell apoptosis. J Immunol. 2001;167(2):667-673.
33. Lin ML, Zhan Y, Villadangos JA, Lew AM. The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol. 2008;86(4): 353-362.
34. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol. 2003;170(6):2817-2823.
35. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61. (Pubitemid 46067386)
36. Sancho D, Joffre OP, Keller AM, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009;458: 899-903.
37. Watkins SC, Salter RD. Functional connectivity between immune cells mediated by tunneling nanotubules. Immunity. 2005;23(3):309-318.
38. Morelli AE, Larregina AT, Shufesky WJ, et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood. 2003;101(2):611-620.
39. Gardai SJ, Bratton DL, Ogden CA, Henson PM. Recognition ligands on apoptotic cells: a perspective. J Leukoc Biol. 2006;79(5):896-903.
40. Gardai SJ, McPhillips KA, Frasch SC, et al. Cellsurface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321-334.
41. Iyoda T, Shimoyama S, Liu K, et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med. 2002; 195(10):1289-1302.
42. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol. 1999;163(1):130-136.
43. Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother. 2004;53(11):963-977.
44. Yasuda T, Kamigaki T, Nakamura T, et al. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Oncol Rep. 2006; 16(6):1317-1324.
45. Uhl M, Kepp O, Jusforgues-Saklani H, Vicencio JM, Kroemer G, Albert ML. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8(+) T cells. Cell Death Differ. 2009;16:991-1005.
46. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother. 1998;46(2):82-87.
47. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419-426.
48. Palucka AK, Ueno H, Fay J, Banchereau J. Dendritic cells: a critical player in cancer therapy? J Immunother. 2008;31(9):793-805.
49. Labarriere N, Bretaudeau L, Gervois N, et al. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer. 2002;101(3):280-286.
50. Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 2002; 62(6):1884-1889.